HeartBeam (NASDAQ: BEAT) has announced a strategic reorganization aimed at accelerating execution, expanding global market reach and improving capital efficiency as it advances commercialization of its cardiac monitoring technology. Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams designed to streamline decision-making, improve accountability and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role.
The company said its strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection. HeartBeam also plans to expand partnerships with governments, health systems, ECG manufacturers and wearable device companies, building on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment. The company's technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. The company holds over 20 issued patents related to technology enablement. Its 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The reorganization is expected to streamline operations and reduce costs, positioning the company for more efficient growth as it targets the global cardiac monitoring market.
The full press release is available at https://ibn.fm/CTxXi. For the latest news and updates relating to BEAT, visit the company's newsroom at https://ibn.fm/BEAT.
This announcement underscores HeartBeam's commitment to transforming cardiac care through innovative technology and strategic partnerships, with the potential to improve outcomes for patients worldwide.
